Phase II Study of Arsenic Trioxide in Patients With Multiple Myeloma
OBJECTIVES: I. Determine the response rate of patients with relapsed or refractory stage II
or III multiple myeloma treated with arsenic trioxide. II. Determine the overall and
relapse-free survival rates of patients treated with this drug. III. Determine the safety
profile of this drug in these patients.
OUTLINE: Patients receive arsenic trioxide IV on days 1-5 and 8-12. Treatment repeats every
4 weeks for up to 6 courses. Patients are followed at 4 weeks after the last treatment dose.
PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.
Primary Purpose: Treatment
Carolyn Paradise, MD
United States: Federal Government
|Swedish Cancer Institute||Seattle, Washington 98104|
|Cleveland Clinic Taussig Cancer Center||Cleveland, Ohio 44195|
|Scripps Clinic||La Jolla, California 92037|
|University of Illinois at Chicago||Chicago, Illinois 60612|
|Rocky Mountain Cancer Center||Denver, Colorado 80218|
|Georgia Cancer Specialist||Marietta, Georgia 30060|